Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23329073 | 0.84 | CA2 (0.53) | CA12CA1CA2CA9EPHX2 | |
| SCHEMBL23329078 | 0.81 | SAE1 (0.56) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL23328728 | 0.81 | RAB9A (0.53) | CA12CA1CA2CA9CA4 | |
| SCHEMBL23328675 | 0.79 | MAPT (0.56) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL23328885 | 0.78 | CYP1A2 (0.42) | CA1CA2CA9EPHX2CA7 | |
| SCHEMBL23328374 | 0.78 | MEN1 (0.59) | CA12CA1CA2CA9EPHX2 | |
| SCHEMBL27710648 | 0.75 | CA12 (0.63) | CA12CA1CA2CA9EPHX2 | |
| SCHEMBL23328882 | 0.74 | RAB9A (0.48) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL23328366 | 0.74 | RAB9A (0.64) | CA12CA1CA2CA9CA4 | |
| SCHEMBL14593707 | 0.73 | EPHX1 (0.67) | CA12CA1CA2CA9EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701333-B2 | Antibacterial compounds | Kent Innovation & Enterprise (GB) | 2023-07-18 | — | — | US | disclosed |
| US-20210128501-A1 | ANTIBACTERIAL COMPOUNDS | KENT INNOVATION & ENTERPRISE, UNIVERSITY OF KENT (GB) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701333-B2 | Antibacterial compounds | ARF1, ARL1, TLR1 | CA12 3999/4885CA1 4609/4885CA2 3565/4885 |
| US-20210128501-A1 | ANTIBACTERIAL COMPOUNDS | ARF1, ARL1, TLR1 | CA12 3999/4885CA1 4609/4885CA2 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.